Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of [<sup>18</sup>F]DCFPyL and [<sup>18</sup>F]FAPI-74 PET/CT imaging in metastatic prostate cancer.

European journal of nuclear medicine and molecular imaging·2026

Same author

First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients.

Acta oncologica (Stockholm, Sweden)·2026

Same author

An unexpected pattern of tracer uptake on pulmonary ventilation/perfusion SPECT imaging: a case report.

European heart journal. Case reports·2026

Same author

Diagnostic performance of contrast-enhanced voiding ultrasonography and direct radionuclide cystography with physiologic bladder filling volumes in pediatric vesicoureteral reflux-a prospective study.

European journal of pediatrics·2026

Same author

Continuous tobacco smoking increases mortality in diffuse large B-cell lymphoma but not follicular lymphoma, a Finnish population-based study.

Acta oncologica (Stockholm, Sweden)·2025

Same author

Lymfactin® gene therapy with vascularized lymph node transfer reduces compression-free swelling and enhances quality of life in breast cancer-related lymphedema: Final Phase I trial results.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

18F-FDOPA: a multiple-target molecule.

Heikki Minn¹, Saila Kauhanen, Marko Seppänen

¹Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland. heminn@utu.fi

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|November 14, 2009

Summary

This summary is machine-generated.

6-(18)F-fluoro-L-dopa (18F-FDOPA) PET/CT imaging aids in diagnosing neuroendocrine tumors (NETs) and pancreatic beta-cell hyperplasia. This advanced imaging technique assists in managing NETs and hyperinsulinemic hyperplasia, potentially improving patient outcomes.

More Related Videos

Genetic Incorporation of Biosynthesized L-dihydroxyphenylalanine (DOPA) and Its Application to Protein Conjugation

Genetic Incorporation of Biosynthesized L-dihydroxyphenylalanine (DOPA) and Its Application to Protein Conjugation

Published on: August 24, 2018

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: Jun 18, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Genetic Incorporation of Biosynthesized L-dihydroxyphenylalanine (DOPA) and Its Application to Protein Conjugation

Genetic Incorporation of Biosynthesized L-dihydroxyphenylalanine (DOPA) and Its Application to Protein Conjugation

Published on: August 24, 2018

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Area of Science:

Nuclear Medicine
Oncology
Endocrinology

Background:

6-(18)F-fluoro-L-dopa ((18)F-FDOPA) has been utilized for dopaminergic system studies for over 20 years.
The diagnostic and therapeutic applications of (18)F-FDOPA PET/CT have expanded significantly beyond its initial use.

Purpose of the Study:

To highlight the expanded role of (18)F-FDOPA PET/CT in diagnosing and managing neuroendocrine tumors (NETs).
To emphasize its utility in identifying pancreatic beta-cell hyperplasia and persistent hyperinsulinemic hyperplasia in infants.
To underscore the benefits of (18)F-FDOPA PET/CT in specialized centers for NET management.

Main Methods:

Positron Emission Tomography (PET) and PET/Computed Tomography (PET/CT) using the tracer (18)F-FDOPA.
Integration of (18)F-FDOPA imaging with receptor-based imaging modalities.
Application in the diagnostic workup of various neuroendocrine tumors and pancreatic pathologies.

Main Results:

(18)F-FDOPA PET/CT enables visualization of NETs and pancreatic beta-cell hyperplasia.
The tracer facilitates management strategies for NETs and hyperinsulinemic conditions.
Expert centers leveraging (18)F-FDOPA PET/CT show significant benefits in NET patient care.

Conclusions:

(18)F-FDOPA PET/CT provides a valuable tool for diagnosing and managing NETs and related hyperplastic conditions.
(18)F-FDOPA-guided therapy can enhance NET control through maximal cytoreduction.
Specialized expertise is crucial for maximizing the benefits of (18)F-FDOPA PET/CT in NET management.